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I. Introduction 
Monoclonal non-specific suppressor factor (MNSF) is 
a lymphokine that is a product of the concanavalin A 
(Con A)-activated murine T cell hybridoma and inhibits 
the generation of lipopolysaccharide (LPS)-induced im- 
munoglobulin secreting cells in an antigen non-specific 
manner [l]. MNSF fractionated on Sephadex G-100 in 
phosphate buffered saline (PBS, pH 7.3) appeared as an 
aggregate with a M, of 70,000, but when fractionated in 
0.5 M pyridine-acetic acid buffer (pH 4.0), it appeared 
as two species of 24,000 and 16,000 Da which showed 
p1 peaks of 5.3 and 5.7, respectively, on isoelectric focus- 
ing [l]. Further purified MNSF using reverse-phase 
HPLC showed a single band with a M, of 12,000 on 
SDS-PAGE. The N-terminal amino acid sequence of the 
protein shows no strong homology to any of the se- 
quences of known biologically active proteins [2]. 
Previous studies on the mode of action of MNSF have 
demonstrated that the target cells involved are both LPS- 
activated B cells and Con A-activated T cells. In addition 
to activated lymphocytes, the function of various tumor 
cell lines of mouse origin is altered by a specific cell 
surface membrane receptor protein [3,4]. More recently, 
we have isolated the human non-specific suppressor fac- 
tor (hNSF) from ascitic fluid of a patient with systemic 
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Abstract 
We investigated whether monoclonal non-specific suppressor factor (MNSF) has an effect on the IL4 secretion by BMMC sensitized with anti-DNP 
IgE monoclonal antibody. The sensitized BMMC showed a maximum increase of IL4 secretion at 10 ng/ml antigen activation. When MNSF (10 U) 
was added, it remarkably suppressed the IL4 secretion (82 + 3%). MNSF also suppressed the IL4 secretion by the mast cell line, CFTL-15, but not 
CFTL-12. Northern blot analysis showed that, when the same amounts of MNSF were added, IL4 mRNA expression was decreased, suggesting 
that the suppression results from the inhibition of a transcript. 
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lupus erythematosus (probably the human counterpart 
of MNSF) and observed that an anti-pan T cell receptor 
CI chain (TCR-a) monoclonal antibody could cross-react 
with it (Xavier, R. et al. (1994) J. Immunol; in press). 
It is evident that transformed or IL3-dependent mur- 
ine mast cell lines [5-81 and murine bone marrow-derived 
mast cells (BMMC) [9,10] can produce a number of cy- 
tokines, like ILl, IL3, IL4, IL5, IL6, IFN-y, GM-CSF, 
TNF-ol, in response to cross-linking of the high affinity 
receptor for IgE (FCE R) or to ionomycin. IL3 has been 
clearly shown to be a mast cell growth factor [l 11; IL4 
is critical for IgE production [ 121; IL5 is a potent eosin- 
ophil differentiation and activation factor [ 131. 
Helper T cells are another cell type known to release 
various lymphokines. However, the activation of these 
lymphokines seems to be largely restricted to the cells 
with which they interact. By contrast, stimulated mast 
cells function by releasing a number of cytokines into the 
extracellular fluid and, therefore, have a wider variety of 
target cells. In this report, we tested the possibility that 
MNSF could be related to the mode of action of BMMC 
from the viewpoint of IL4 secretion. 
2. Materials and Methods 
2.1. Materials 
MNSF was obtained from the ascites of Fl mice (AKR/J/Balb/c) 
after injection of MNSF-producing El7 hybridoma into the peritoneal 
cavity. Purification with the use of anti-MNSF monoclonal antibodv 
(MO@ was done as described previously [14]. The MNSF was furthe; 
purified by combination of ODS-120T and phenyl 5PW reverse-phase 
HPLC column (Tosoh Corp., Tokyo Japan). 1 U of MNSF activity was 
defined as the amount that causes 50% suppression of LPS-induced 
All rights reserved. 
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antibody responses by mouse splenocytes when added at culture mitia- solubihzed granules were then diahzed against PBS and tested for IL4 
tion [l]. by ELISA. 
2 2. Cell culture 2 6. Northern blot analysis 
Mouse BMMC were obtained by culturing bone marrow cells of 
female (IO-12 week old) Balblc mice (Clear, Japan) for 3 weeks in 25% 
WEHI- conditioned medium and 75% enriched medium (RPM11640 
containing 10% FBS, 100 U/ml penicillin, lOO,@ml streptomycin, 2 mM 
L-glutamine, 0.1 mM non-essential amino acids, 0.1 mM 2-mercap- 
toethanol). BMMC contained >95% mast cells according to Neutral 
red staining [15]. CFTL-12 and CFTL-15 were obtained by culturing 
fetal liver from NFS/N mice in IL3 [16]. 
2.3. Senslttation and challenge of BMMC and mast cell Imes 
Either anttgen-activated BMMC (2 x 10’ cells) or mast cell lmes 
(CFTL-12, 5 x 10’; CFTL-15, 2 x 10’ cells) were cultured in the pres- 
ence or absence of MNSF (10 U). harvested and the total cellular RNA 
was isolated by the methods of Sambrook et al. [19]. 2Opg of RNA was 
fractioned on 1% agarose formaldehyde gels. and transferred to ECL- 
Hybond. Hybridization, labeling of cDNA probe and detection were 
done according to the ECL-Gene Detection System (Amersham). The 
mouse IL4 cDNA probe was a 424 bp EcoRI-Hind111 fragment which 
Includes the 373 bp RsaI fragment of mouse IL4 cDNA and 51 bp of 
pGEM-3 [l I]. 
BMMC, CFTL-12 or CFTL-15 (1 x 105cells/ml) were sensitized with 
1 pg/ml of anti-dinitrophenyl (DNP) IgE monoclonal antibody for 3 h 
m 25% WEHI-3-conditioned medium/75% enriched medium described 
above (BMMC) or the enriched medium only (cell lines) and were then 
washed three times with Hank’s balanced salt solution (HBSS). To 
measure IL4 secretion in the culture medium, the cells were resuspended 
in 25% WEHI- conditioned/75% enriched medium at a concentration 
of 1 x lO’/ml and challenged with DNP2,-BSA antigen (10 &ml) for 
6 h. 
3. Results and Discussion 
2 4. Enzyme-hnked imnwnosorbent ussay (ELISA) for IL4 
To measure mouse IL4, a sandwich ELISA was developed by using 
two distinct rat monoclonal antibodies to IL4. Briefly, the first antibody 
(Pharmmgen; #18031) was coated onto ELISA plates (Nunc, Den- 
mark; 0.2 &well) and then samples obtained from BMMC or mast cell 
line cultures were added. Subsequently, the biotinylated rat anti-mouse 
IL4 monoclonal antibody (Pharmingen; #18024) at 0.1 pug/well was 
added and then streptavidin-alkaline phosphate at 80 @well. The 
plates were washed with PBS/O.OS% Tween 20 at each step of this 
procedure. The alkaline phosphatase substrate was in 0.1 M 2-amino- 
ethanol (Sigma), 1 mM MgCl,, pH 9.8. Sensitivity was 1 U/ml. The 
umtage was defined by the CT-4S proliferative assay as the concentra- 
tion required for half-maximal stimulation [17]. 
While studying possible effects of MNSF on mast 
cells, we observed that it greatly influenced the produc- 
tion of IL4 by mast cells, and this is the subject of the 
present report. In preliminary experiments, we had ob- 
served that the maximum increase in IL4 secretion by 
activated BMMC was detected after 6 h of antigen stim- 
ulation. To obtain an optimal condition of antigen con- 
centration to activate BMMC, anti-DNP IgE-sensitized 
BMMC were tested for the maximum increase of IL4 
secretion (Fig. 1). A concentration of 10 @ml of DNP- 
BSA resulted in a maximum increase, and hence was 
used for studies of the following inhibition tests. 
2.5. Analvsis of IL4 stored m granules of BMMC 
MNSF was added to BMMC cultures at the time of 
antigen challenge. The secretion of IL4 was inhibited, 
dose dependently, by the addition of MNSF (Fig. 2A). 
However, complete suppression of IL4 secretion was not 
observed, suggesting that some of the secreted IL4 could 
have been preformed and stored in granules. We tested 
this possibility by disrupting BMMC and detecting the 
amounts of stored IL4 as described in section 2. Table 1 
shows that little IL4 could be detected after disrupting 
BMMC, indicating that IL4 was released from newly 
Cytoplasmic granules were prepared by the method of Roussel and 
Greenberg 1181. In brief. cells were washed in HBSS and resuspended 
m disrup&r buffer (0.25 M sucrose, 0.01 M HEPES, 4 mM EGTA, 
pH 7.4). They were lysed by decompression at 0°C after equilibrating 
at 450 psi nitrogen for 20 mm. After the addition of MgClz to 5 mM. 
the homogenate was digested with DNase I (from bovine pancreas, type 
IV. Sigma) at 1.000 U/ml, 22’C, 30 min. Nuclei were removed by 
filtration through Nucleopore filters (Nucleopore) and the resulting 
homogenate was cooled to 0°C. 5 ml aliquots were layered on 20 ml 
of 48% PercoIl and ultracentrifuged (60,000 x g) for 10 min. The re- 
sulting gradient was fractionated from the bottom by insertion of a 
stainless- steel tube from the top, and the first 5 ml high-density Percoll 
fraction was removed via attached polyethlene tubing. Granules have 
been shown to the present in the high-density Percoll fractions on the 
basis of granule markers such as /I-glucuronidase and cytolysin. To 
eliminate the Percoll, the granule fractions were ultracentrtfuged 
(85.000 x g) for 2 h. and then the granules were removed and diluted 
with sterile water and then stored at -70°C. The granules were quickly 
thawed at 37°C and then solubilized m 3 M NaCl for 1 h on ice. The 
Table 1 
Pre-formed IL4 in BMMC 
Total amounts detected (U/ml)* 
Experiment 1 Experiment 2 
Unsensitized BMMC 
Sensitized BMMC 
853 521 
24 f 5 15+3 
*Purification of BMMC (1 x 10’ cells) cytoplasmic granules and detec- 
tion of the amount of IL4 were done as described in section 2. The 
amount of IL4 obtained from the same number of sensitized and anti- 
gen-stimulated BMMC was 728 ? 66 U/ml. 
DNP-BSA (q/ml) 
Fig. 1. Effect of various concentrations m DNP-BSA antigen on the IL4 
secretion by BMMC. BMMC (2 x lo”, n ; 1 x lo5 cells, 0) were sensi- 
tized with anti-DNP-BSA IgE monoclonal antibody (1 @ml) and then 
challenged with DNP-BSA antigen (10 ng/ml). IL4 secreted into the 
BMMC culture supernatant was detected by ELISA as described in 
section 2. Experimental values are means of triplicate determinations. 
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Fig. 2. (A) Effect of MNSF on IL4 secretion by BMMC. BMMC (1 x IO’ cells) were sensitized and challenged with antigen as described in the legend 
to Fig. 1. Various concentrations of MNSF were added at the initiation of the cultures. For controls, PBS was added in piace of MNSF. Secreted 
IL4 was detected and percentage suppression was calculated by comparison with the control response of 462 U/ml. (B) Kinetics of suppression of 
MNSF. MNSF was added to the BMMC cultures at indicted times; e,, 10 U MNSF added; 0,5 U. Percentage suppression was estimated as described 
in the legend to Fig. 2. 
synthesized pools and not stored in granules after sensiti- 
zation. We speculate that the incomplete effect might be 
due to the following reasons. First, an alternative path- 
way not influenced by MNSF might exist. Second, the 
presence of an inhibitor, for instance, soluble MNSF 
receptor, may control the function. 
The kinetics of suppression of MNSF were examined 
to determine whether MNSF would also suppress IL4 
secretion during various periods of culture. As can be 
seen in Fig. 2B, maximum suppression was observed 
when MNSF was added at the time of antigen challenge, 
whereas no significant effect could be detected when it 
was added during the later culture period, thereby indi- 
cating that MNSF acts on BMMC at an early stage, In 
contrast, MNSF inhibits the antibody response in all 
culture periods f3]. 
We investigated whether suppression of IL4 secretion 
could also be observed in murine mast cell lines. MNSF 
inhibited the secretion of IL4 in CFTL-15, whereas no 
significant suppression was observed in CFTL-12 
(Fig. 3). CFTL-15 would be a good model to investigate 
loo 1 
0 IO 20 30 
MNSF added (U/ml) 
Fig. 3. Effect of MNSF on the IL4 secretion by mouse mast cell lines. 
CFTL-12, O; and CFTL-15, O; were sensitized and challenged as de- 
scribed in section 2. Control and stimulated levels of IL4 production 
were 18 and 231 U/ml for the CFTL-12, and 61 and 558 U/m1 for the 
CFTL-15 cell line. 
the functional mechanism of MNSF. It is conceivable 
that MNSF can not act on CFTL-12 due to lack of 
MNSF receptors on the cell surface. It is unclear at 
present whether MNSF acts directly on BMMC. Binding 
assays of ‘“SI-labelled MNSF to BMMC are under way 
to clarify receptor expression on the cells. We reported 
previously that IFN-y-activated murine spleen cells pro- 
duce MNSF, and that IFN-y enhances the activity of 
MNSF on target cells by an increment related to the 
number of MNSF receptors [20,21]. Further studies are 
in progress to determine whether IFN-y is involved in 
the functional mechanism of BMMC. 
To determine whether the suppression of IL4 secretion 
resulted from a decrease in the normal stimulated accu- 
mulation of IL4 mRNA, Northern blot analyses were 
carried out. As can be seen in Fig. 4A, the expression of 
A 
I2 3 
I 
-18 S 
B 
1 2 3 4 
-IL4 -IL4 
-@-actin 
-@-actin 
Fig. 4. Northern blot analysis of IL4 mRNA. (A) Poly(A*) RNA 
(2O~~ane), obtained from 2 x 10’ BMMC activated with antigen in 
the absence (lane 1) or presence (lane 2) of MNSF (IO II), were size- 
separated and blotted onto nitrocellutose and hybrid&d with the probe 
for IL4 (upper bands) or /J-actin (bottom bands). Lane 3 shows the 
basal level of IL4 mRNA. The migrated positions of 18 S ribosomal 
RNA are indicated in the RNA blots. (B) Poly(A’) RNA (20&lane), 
obtained from mast cell lines activated with antigen in the absence 
(lanes I and 3) or presence (lanes 2 and 4) of MNSF (10 U), were probed 
with IL4 cDNA; lanes I and 2, CFTL-15 (2 x 10’ ceils); lanes 3 and 4, 
CFTL-12 (5 x lo7 ceils). 
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IL4 mRNA was inhibited in the presence of MNSF in 
the BMMC culture. The incomplete suppression of IL4 
mRNA expression might be comparable to that of IL4 
secretion. No IL4 mRNA was expressed in BMMC in 
the absence of antigen. In CFTL-15 cells, MNSF inhib- 
ited the IL4 mRNA expression to the same extent as in 
BMMC, while this effect was not observed in CFTL-12 
(Fig. 4B). In the absence of antigen, the basal levels of 
IL4 mRNA in both CFTL-12 and -15 cells were nil 
(data not shown). It remains to be clarified whether or 
not the suppression is a consequence of a decreased rate 
of transcription and/or increase in specific RNase that 
degrades the transcripts. 
Further studies are currently in progress to clarify the 
specific mode of action of MNSF in BMMC. We are 
now attempting to isolate cDNA for MNSF and hNSF 
by the use of synthetic oligonucleotide primers corre- 
sponding to the N-terminal amino acid sequences of 
MNSF. 
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